Sign up


Match Document Document Title
6165459 Methods for suppressing myeloid cells with chemokines  
Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while...
6162427 Combination of G-CSF with a chemotherapeutic agent for stem cell mobilization  
The invention relates to the use of G-CSF in combination with a chemotherapeutic agent (in particular, cyclophosphamide) to produce a pharmaceutical preparation for boosting the mobilization of...
6162426 Use of G-CSF to enhance the immune system in neonates  
The invention relates to the use of Granulocyte Colony Stimulating Factor (G-CSF) to enhance the immune system in neonates by increasing the Absolute Neutrophil Count and/or increasing the Fcγ...
6159460 Method for treating interleukin-1 mediated diseases  
The present invention provides methods for treating interleukin-1 mediated diseases including arthritis, inflammatory bowel disease, sepsis and septic shock, ischemia injury, reperfusion injury,...
6159461 Use of c-kit ligand with TNF-α and hematopoietic factors for the expansion or differentiation of hematopoietic cells  
Compositions comprising c-kit ligand, TNF-α, and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic...
6159463 Lymphocyte chemoattractant factor  
Purified DNA encoding LCF and the recombinant proteins expressed from such DNA are disclosed. In addition, the invention provides methods for suppressing an LCF-CD4 interaction and screening...
6159462 Uses of Wnt polypeptides  
Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation, differentiation or maintenance of a hematopoietic stem/progenitor...
6156300 Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6156302 Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes  
The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic...
6156729 Leukemia inhibitory factor for use in modulating inflammation and pain  
A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in...
6153407 Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics  
Provided are nucleic acids encoding erythropoietin (EPO) proteins and having modifications in the 5' and 3' noncoding sequences relative to the corresponding sequences in native EPO DNA. The...
6143866 Tumor necrosis factor (TNF) inhibitor and method for obtaining the same  
At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from...
6143289 Compositions of myeloid-cell-suppressive chemokines  
Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory...
6139832 Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides  
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human chemokine beta-11 (Ck beta-11) polypeptide and a human leukocyte adhesion...
6130318 hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4  
The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions...
6126933 Methods of treating inflammatory bowel diseases by administering IL-11  
Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease,...
6120760 Growth/differentiation factors of the TGF-β family  
The invention provides DNA sequences encoding novel members of the TGF-β family of proteins. The TGF-β family comprises proteins which function as growth and/or differentiation factors and which...
6117422 N∇2-CSF-1(long form) and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6113900 Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders  
Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as...
6110695 Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1  
The invention provides methods for identifying agents which modulate the interaction of a chemokine receptor of previously unknown function, Burkitt's Lymphoma Receptor 1 (BLR1), with its ligand,...
6110459 Transplants for myocardial scars and methods and cellular preparations  
A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal...
6110891 Lectin compositions and uses thereof  
This invention provides methods for: the control of mucosal cell proliferation; the reduction and/or treatment of damage caused by a cell-damaging agent; and for the reduction and/or treatment of...
6106822 Hormone and growth factor phosphoglycokine mimetics from mycobacterium  
A hormone or growth factor mimetic second messenger is derived from a microorganism of the genus Mycobacterium, suitably M. vaccae. The mimetic second messenger may mimic the action of insulin,...
6103224 N∇2 CSF-1 (short form) and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6099846 Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates  
B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This...
6096300 Treatment of myeloproliferative disease with exodus chemokine  
The present invention provides purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production...
6096320 Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica  
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
6093381 Modulation of the sensitivity of tumor cells to chemotherapeutics  
Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the...
6093699 Method for gene therapy involving suppression of an immune response  
A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question, which response is...
6093390 Methods for promoting functional regeneration of mammalian muscle by administering leukaemia inhibitor factor  
The present invention relates to a method for regulating neuron development, maintenance and regeneration in the central and peripheral nervous systems of a mammal and to pharmaceutical...
6093405 Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines  
Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when...
6093391 Peptide copolymer compositions  
Compositions of peptides and block copolymers and methods of treatment using the same. The compositions enhance the activity of peptide-based and related biological agents, and reduce adverse side...
6090377 Monocyte activating cytokine  
The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells...
6090918 Receptor protein designated 2F1  
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting...
6086866 Use of platelet-derived growth factor to improve collateral circulation  
The present invention provides a non-invasive method for improving collateral circulation to tissue at risk of ischemia or ischemic necrosis. Improved collateral circulation is obtained by...
6086868 Method for treating or preventing ischemia-reperfusion injury  
There is disclosed a method of treating ischemia-reperfusion injury comprising administering an effective amount of Interleukin-10 to a patient suffering or expected to suffer from such injury.
6086867 Modulation of TGF-β by TGF-β type III receptor polypeptides  
DNA encoding TGF-β TYPE III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor. TGF-β type II receptor and uses therefor.
6086865 Methods of treating angiogenesis-induced diseases and pharmaceutical compositions thereof  
The present invention provides for the use of fumagillin or an O-substituted fumagillol derivative in conjunction with interferon which increases the angiogenic inhibitory action as compared with...
6083907 Treatment of peptic ulcers using midkine (MK) proteins  
An anti-ulcer composition is provided, which comprises as an active ingredient at least one of MK protein, its derivative having biological activity of MK protein, and their fragment having...
6084071 Human L105 polypeptides and polynucleotides encoding same  
A chemokine, human L105, is disclosed.
6083534 Pharmaceutical compositions for controlled release of soluble receptors  
A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a...
6083906 Method of regulating nitric oxide production or arthritis with soluble IL-17 receptor  
Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
6083503 Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection  
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T...
RE36755 DNA encoding tumor necrosis factor-α and -β receptors  
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
6080398 Truncated gro and KC chemokines having enhanced bioactivity  
The present invention provides method of increasing the biological activity of KC, gro-α, gro-β, and gro-γ proteins, truncated and modified proteins characterized by having biological activity at...
6077519 Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients  
Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide...
6074635 T cell activation  
Methods for activating T cells in the absence of antigen, and compositions for effecting the same, are described.
6074639 Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins  
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
6066318 Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors  
Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the...
6063372 Uses of mammalian CTLA-8 and related reagents  
Compositions and methods for using CTLA-8 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or...